Trial Profile
Ultra-wide Fluorescein angiograpHy to Evaluate the Progression of Retinal ischeMia After aflibErcept Injections in patientS With Central Retinal Vein Occlusion in Real Life (HERMES Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms HERMES; HERMES Study
- 27 Jun 2023 Status changed from active, no longer recruiting to completed.
- 17 Aug 2022 Planned End Date changed from 30 Mar 2022 to 30 Nov 2022.
- 17 Aug 2022 Planned primary completion date changed from 30 Mar 2022 to 30 Oct 2022.